晚期前列腺癌中与生存不良及体细胞肿瘤改变相关的胚系多态性
本研究对101例转移性去势抵抗性前列腺癌(mCRPC)患者进行胚系和体细胞全基因组测序,分析雄激素代谢基因胚系变异与ADT后总生存(OS)的关系。发现HSD3B1上游13 kb的rs1856888变异与OS不良显著相关(P=0.029),且常与HSD3B1(1245A>C)共遗传,后者显示OS缩短趋势(P=0.052)。这些胚系变异与肿瘤细胞增殖和细胞周期基因表达增加相关。
要点
- rs1856888变异与mCRPC患者ADT后总生存不良显著相关。
- rs1856888常与HSD3B1(1245A>C)共遗传,后者显示OS缩短趋势。
- HSD3B1胚系变异与肿瘤细胞增殖和细胞周期基因表达增加相关。
核心结论
- HSD3B1多态性与mCRPC患者ADT后总生存不良相关,并与侵袭性基因表达谱相关。
研究设计与样本
- 对101例mCRPC患者进行胚系和体细胞全基因组测序,并进行生存分析。
主要发现
- rs1856888变异与 impaired OS 显著相关(P=0.029)。
- HSD3B1(1245A>C)与野生型纯合子相比,中位OS缩短趋势(P=0.052)。
- HSD3B1胚系变异与肿瘤细胞增殖和细胞周期基因表达增加相关。
关键数值与推荐
- 文献回顾确定9个雄激素代谢基因中的17个候选多态性。
- rs1856888位于HSD3B1上游13 kb。
临床怎么用
- HSD3B1胚系变异可能作为ADT后生存预后的生物标志物。
- 需进一步验证以指导个体化治疗。
局限性
- 样本量较小(101例)。
- 未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Germline variants in androgen metabolism genes may influence clinical response to androgen deprivation therapy (ADT) in advanced prostate cancer. We sought to investigate the prognostic significance of germline variants in androgen metabolism genes with respect to overall survival (OS) after ADT, and to associate germline variants with tumor genomic features. METHODS: Germline and somatic whole-genome sequencing (WGS) data were evaluated in a cohort of 101 men with metastatic castration-resistant prostate cancer (mCRPC). Survival analyses were performed to identify polymorphisms associated with impaired OS after primary ADT. Germline variants found to be prognostic of OS were associated with tumor somatic DNA-sequence alterations based on WGS performed on paired metastasis biopsies from the same 101 patients. Gene set enrichment analysis was performed based on tumor RNA-sequencing data to identify genomic pathways differentially expressed in patients with germline variants. RESULTS: A comprehensive literature review identified 17 candidate polymorphisms in nine androgen metabolism genes that have been previously shown to have an association with response to ADT in prostate cancer. Of these, the variant rs1856888 allele located 13 kb upstream of HSD3B1 was found to be significantly associated with impaired OS (P = 0.029). Variant rs1856888 was commonly co-inherited with the well-characterized HSD3B1(1245A>C) polymorphism, and there was a trend toward shorter median OS in patients with HSD3B1(1245A>C) compared with homozygous wild-type patients (P = 0.052). While HSD3B1 germline variants were not associated with common somatic tumor DNA alterations, they were associated with increased tumor expression of cell proliferation and cell cycle genes. CONCLUSIONS: This study presents a comprehensive assessment of germline variants in androgen metabolism genes and highlights HSD3B1 polymorphisms as prognostic of OS after ADT and associated with an aggressive gene expression tumor profile in mCRPC.
引用
- Chen WS, Feng EL, Aggarwal R, et al. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 31745256. doi:10.1038/s41391-019-0188-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。